StreetInsider.com News Articles

FDA grants Jaguar Health fee waivers for two drugs in fiscal 2027

Tue, 22 Sep 2026 09:06:20 -0400

Jaguar Health, Inc. (NASDAQ: JAGX) announced that the U.S. Food and Drug Administration has granted fee waivers under the Prescription Drug User Fee Act for two of its drugs for the 2027 fiscal year, according to a company press release.

Napo Pharmaceuticals, a Jaguar family company, received a waiver of the PDUFA fee for Mytesi (crofelemer delayed-release tablets). Mytesi is an FDA-approved prescription drug for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy. The drug is currently commercialized in the U.S. by Future Pak, LLC.

Jaguar also received a separate waiver from the FDA's Center for

FDA grants Jaguar Health fee waivers for two drugs in fiscal 2027

Tue, 22 Sep 2026 09:06:20 -0400

Jaguar also received a separate waiver from the FDA's Center for

Jaguar Health Receives Fee Waivers from FDA

Tue, 22 Sep 2026 09:05:00 -0400

SAN FRANCISCO, CA / ACCESS Newswire / September 22, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that the U.S. Food and Drug Administration (FDA) has granted Napo's request for a waiver of the fee associated with the Prescription Drug User Fee Act (PDUFA) for Mytesi^® (crofelemer delayed-release tablets) for the 2027 fiscal year. Mytesi is an FDA-approved prescription drug for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy, and is currently

Jaguar Health Receives Fee Waivers from FDA

Tue, 22 Sep 2026 09:05:00 -0400

Form 8-K Jaguar Health, Inc. For: Sep 15

Mon, 21 Sep 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260921/27085864.html

Form PRE 14A Jaguar Health, Inc. For: Oct 23

Fri, 18 Sep 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260918/27081331.html

Form 8-K Jaguar Health, Inc. For: Sep 11

Tue, 15 Sep 2026 13:45:00 -0400

si-local-file:///var/storage/secattach/20260915/27064180.html

Form 8-K Jaguar Health, Inc. For: Sep 14

Tue, 15 Sep 2026 09:10:00 -0400

si-local-file:///var/storage/secattach/20260915/27062471.html

Jaguar Health announces 1-for-15 reverse stock split on Nasdaq

Tue, 15 Sep 2026 09:01:16 -0400

Jaguar Health, Inc. (Nasdaq: JAGX) announced it will execute a 1-for-15 reverse stock split of its common stock, effective September 17, 2026, to support compliance with Nasdaq's listing standards.

Under the terms of the split, every 15 shares of common stock will be reclassified into one share, with no change to the par value per share. Shares will begin trading on a split-adjusted basis when the market opens on the effective date and will continue to trade on the Nasdaq Capital Market under the symbol "JAGX." The new CUSIP number for the common stock will be 47010C854.

The reverse stock split was

Jaguar Health, Inc. Announces Reverse Stock Split

Tue, 15 Sep 2026 09:00:00 -0400

Reverse split approved at April 2026 Special Meeting of Stockholders

Shares of Jaguar Health common stock to begin trading on split-adjusted basis on September 17, 2026

SAN FRANCISCO, CA / ACCESS Newswire / September 15, 2026 / Jaguar Health, Inc. (Nasdaq:JAGX) ("Jaguar" or the "Company") today announced that the Company will effect a reverse stock split of its issued and outstanding voting common stock ("Common Stock"), at an exchange ratio of 1-for-15, on Thursday, September 17, 2026 (the "Effective Date") in order to support the Company's compliance with Nasdaq's

Jaguar Health, Inc. Announces Reverse Stock Split

Tue, 15 Sep 2026 09:00:00 -0400

Reverse split approved at April 2026 Special Meeting of Stockholders

Shares of Jaguar Health common stock to begin trading on split-adjusted basis on September 17, 2026

Jaguar Health MVID trial moves to extension phase ahead of 2027 NDA

Thu, 10 Sep 2026 09:01:45 -0400

Jaguar Health, Inc. (NASDAQ: JAGX) subsidiary Napo Pharmaceuticals announced that all randomized pediatric patients in its pivotal crossover clinical trial of crofelemer for microvillus inclusion disease (MVID) with intestinal failure have entered a single-blind extension phase, according to a press release dated September 10, 2026.

The extension phase will have patients receive blinded doses of crofelemer powder for oral solution as adjunctive therapy to parenteral support. The trial is running at multiple centers in the United States, the European Union, and the United Arab Emirates. Napo expects the data to support a New Drug Application filing for the MVID indication in

All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failu

Thu, 10 Sep 2026 09:00:00 -0400

Continuation of treatment with blinded doses of crofelemer in the extension phase of the trial will support company's plans to file an NDA in mid-2027 for MVID, an ultrarare pediatric disease

SAN FRANCISCO, CA / ACCESS Newswire / September 10, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that all randomized pediatric MVID patients in Napo's pivotal crossover clinical trial have entered the single-blind extension phase to receive blinded doses of crofelemer to support longer-term safety and efficacy for crofelemer

All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failu

Thu, 10 Sep 2026 09:00:00 -0400

Continuation of treatment with blinded doses of crofelemer in the extension phase of the trial will support company's plans to file an NDA in mid-2027 for MVID, an ultrarare pediatric disease

Now Available on Amazon: Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs

Tue, 08 Sep 2026 09:00:00 -0400

Neonorm^® Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool consistency and GI fluid balance in dogs

Jaguar expects Neonorm Dog to be available through other select online and animal health retail channels shortly, including Chewy

SAN FRANCISCO, CA / ACCESS Newswire / September 8, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Neonorm Dog is now available on Amazon. A new extension of Jaguar's Neonorm franchise for

Now Available on Amazon: Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs

Tue, 08 Sep 2026 09:00:00 -0400

Jaguar expects Neonorm Dog to be available through other select online and animal health retail channels shortly, including Chewy

Jaguar Health provides crofelemer to infant for compassionate use

Fri, 04 Sep 2026 08:33:48 -0400

Jaguar Health, Inc. (NASDAQ: JAGX) announced that its subsidiary Napo Pharmaceuticals is providing crofelemer powder for oral solution to an infant patient with intestinal failure (IF) caused by congenital sodium diarrhea (CSD), the result of a mutation in the GUCY2C gene.

The treatment is being administered as adjunctive therapy to parenteral support (PS) under a compassionate use arrangement, according to a company statement. The goal is to reduce the infant's daily and weekly PS requirements, consistent with outcomes observed in other pediatric IF patients.

Jaguar said it has completed the randomized double-blind treatment phase of a pivotal clinical trial of liquid oral

Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF)

Fri, 04 Sep 2026 08:30:00 -0400

Jaguar remains sharply focused on its ongoing global development program for oral crofelemer as adjunctive therapy to parenteral support (PS) for pediatric and adult rare IF diseases, including microvillus inclusion disease (MVID)

Company plans to file NDA for crofelemer for MVID in mid-2027 to obtain FDA approval

SAN FRANCISCO, CA / ACCESS Newswire / September 4, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Jaguar family company Napo Pharmaceuticals (Napo) is providing the company's novel crofelemer powder for oral solution for treatment of intestinal failure

Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF)

Fri, 04 Sep 2026 08:30:00 -0400

Company plans to file NDA for crofelemer for MVID in mid-2027 to obtain FDA approval

Jaguar Health launches Neonorm Dog for canine digestive support

Wed, 26 Aug 2026 09:01:21 -0400

Jaguar Health, Inc. (NASDAQ: JAGX) announced the commercial launch of Neonorm Dog, a plant-based, non-prescription product intended to support normal stool consistency and gastrointestinal fluid balance in dogs.

The product extends Jaguar's existing Neonorm franchise, which currently includes Neonorm Foal and Neonorm Calf. Like those products, Neonorm Dog contains a standardized botanical extract derived from the Croton lechleri tree. The company said the product is not intended to diagnose, treat, cure, or prevent any disease, and is not a substitute for veterinary care.

Jaguar said it expects Neonorm Dog to become available through Amazon and Chewy, as well as select animal health

Commercial Launch Initiated for Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs

Wed, 26 Aug 2026 09:00:00 -0400

Jaguar expects to make Neonorm Dog available through both Amazon and Chewy soon

SAN FRANCISCO, CA / ACCESS Newswire / August 26, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced the initiation of the commercial launch of Neonorm Dog, a new extension of Jaguar's Neonorm franchise for companion and production animals. Neonorm Dog is

Commercial Launch Initiated for Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs

Wed, 26 Aug 2026 09:00:00 -0400

Jaguar expects to make Neonorm Dog available through both Amazon and Chewy soon

Form 424B3 Jaguar Health, Inc.

Fri, 21 Aug 2026 15:01:00 -0400

si-local-file:///var/storage/secattach/20260821/26960962.html

Form 424B3 Jaguar Health, Inc.

Fri, 21 Aug 2026 15:01:00 -0400

si-local-file:///var/storage/secattach/20260821/26960962.html

Jaguar Health (JAGX) Tops Q2 EPS by 3647c

Wed, 19 Aug 2026 17:25:52 -0400

Jaguar Health (NASDAQ: JAGX) reported Q2 EPS of ($15.68), $36.47 better than the analyst estimate of ($52.15). Revenue for the quarter came in at $1.23 million versus the consensus estimate of $4.24 million.

For earnings history and earnings-related data on Jaguar Health (JAGX) click here.